Abstract
Peripheral oxygen saturation (SpO2) using the fingers may have important limitations due to Raynaud’s phenomenon and sclerodactyly in patients with systemic sclerosis (SSc). Sensors located at more central body positions may be more accurate as these as less prone to Raynaud attacks. To determine the validity and reliability of the SpO2 measured at the finger, forehead, and earlobe during the 6-Minute Walk Test (6MWT). Eighty two patients with SSc had an arterial line placed while performing the 6MWT. Peripheral oxygen saturation was simultaneously measured by finger, forehead, and earlobe sensors and compared to the arterial oxygen saturation (SaO2) measured before and after the 6MWT. 40 patients repeated the 6MWT one week later to determine re-test reliability. We used Bland–Altman plots to display the agreement between SpO2 and SaO2. The intraclass correlation coefficient for repeated measurement of minimum SpO2 was calculated. The mean difference between SpO2 and SaO2 after the 6MWT was − 3% (SD: ± 5), 0% (SD: ± 2), and 1% (SD: ± 2) for the finger, forehead, and earlobe, respectively. The minimum SpO2 measured at the finger demonstrated the poorest re-test reliability: The ICC (95% CI) showed good agreement using the ear and forehead probe (ICCear = 0.89 [95% CI 0.80; 0.94]; ICCforehead = 0.77 [95% CI 0.60; 0.87]), while a modest reliability was found using the finger probe (ICCfinger = 0.65 95% CI [0.43; 0.80]). SpO2 should be measured using either the earlobe or forehead during the 6MWT in patients with SSc. Clinical Trials.Gov (NCT04650659).
Supplementary Information
The online version contains supplementary material available at 10.1007/s00296-024-05532-5.
Keywords: Reproducibility of Results, Oximetry, Walk Test, Scleroderma, Systemic
Introduction
Systemic sclerosis (SSc) is a progressive chronic connective tissue disease characterized by microvasculopathy and extensive fibrosis in the skin and internal organs. The disease has an increased mortality, with SSc associated interstitial lung disease (SSc-ILD) and pulmonary arterial hypertension (SSc-PAH) accounting for the majority of SSc-related deaths [1]. The peripheral microvasculopathy in SSc leads to poor perfusion of the fingers, which manifest as Raynaud’s phenomenon, digital ulcers, and poor healing. Overt symptoms of fibrosis include thickness of the skin, dry skin and contractures of the joints [2]. Many patients with SSc have decreased exercise tolerance, which may have multiple aetiologies, in which musculoskeletal disease, internal organ involvement, and deconditioning may play a role [3]. The disease progression is highly variable, and accurate markers of disease activity is essential for qualified management of the disease.
The 6-Minute Walk Test (6MWT) is a standardized non-invasive sub-maximum exercise test. During the 6MWT, the distance (6MWD), effort, and peripheral oxygen saturation (SpO2) are registered [4]. The test is primarily used as an outcome measure of clinical SSc trials, to monitor treatment response in patients with pulmonary involvement, and as a measure of functional capacity in general [5].
Exercise-induced desaturation during the 6MWT is associated with the degree of dyspnea, diffusion capacity for carbon monoxide and the extent of lung fibrosis HRCT in patients with SSc [6–9]. Furthermore, SpO2 desaturations have been associated with progression of SSc-ILD and poorer prognosis in patients with SSc [10, 11].
While digital sensors are commonly used to measure SpO2 during the 6MWT, these measurements may have important limitations in patients with SSc due to disease related microangiopathy, Raynaud’s phenomenon, sclerodactyly and motion artifacts during the 6MWT [12]. Consequently, finger probe pulse oximetry may cause inaccurate measures of SpO2, and there may be substantial variation of SpO2 measurements in patients with SSc [13, 14]. Indeed, several authors author advocate for measuring Sp02 at the forehead in patients with SSc [5, 7]. Still, the evidence for measuring Sp02 at more central locations is based on only a single study examining the re-test reliability of SpO2 measurement during the 6MWT in a small cohort of patients with SSc [7].
We aimed to determine the validity and re-test reliability of peripheral oxygen saturation measured at the finger, forehead, and earlobe as compared with blood gas analysis during the 6MWT in patients with SSc.
Methods
Study population and study design
We conducted a cross-sectional study at the Department of Rheumatology at Aarhus University Hospital in Denmark from 27 July 2021 to 21 December 2021 involving adult patients diagnosed with SSc according to the ACR/EULAR 2013 criteria [15].
Patients were excluded in case of recent or ongoing pneumonia, pregnancy, a diagnose of connective tissue overlap syndrome [16] or in case of severe physical or mental comorbidity, which prevented the performance of the 6MWT. Patients were allowed to use supplemental oxygen or walking aid during the 6MWT if needed.
6MWT and measurements of oxygen saturation
The 6MWT was performed at room temperature by the same investigator (ALE) according to the American Thoracic Society guidelines [4]. Patients had acclimatised and rested for minimum 20 min before test start. SpO2, 6MWD and Borg dyspnoea score were collected [4, 17]. Raynaud’s attacks during the 6MWT were noted in case the patient fingers turned white and/or blue. SpO2 was continuously measured during the 6MWT by pulse oximeters (Vyntus® WALK, Nonin Model 3150, Viare Medical, Germany) using sensors at the finger, earlobe and forehead [18]. The pulse oximeters measured SpO2 as integers. The accuracy of the SpO2 measurement (interval of 70–100%) with low perfusion was ± 2%. At the first visit, an arterial line was placed in all patients by a trained anesthesiologist (HH or PJ) on the opposite arm of the finger oximetry sensor. Arterial blood was drawn immediately before (pre-exercise) and after (post-exercise) the 6MWT and analysed with a blood gas analyser (ABL800, Radiometer Medical, Brønshøj, Denmark).
A subgroup of patients (n = 40) repeated the 6MWT one week later without an arterial line. At visit 2 the earlobe and finger probe were placed on the same earlobe and finger as in visit 1 (Supplementary Fig. 1).
Data quality
The oximeters were electronic and paired with tablets via Bluetooth, which generated a graph of the continuous measurement of SpO2 during the 6MWT (Supplementary Fig. 2). The quality of data was assessed by ALE using the following pre-specified criteria for exclusion of data (Supplementary Table 1).
(1) Technical error in collection or transfer of data from pulse oximeter and tablet (i.e., no readings from pulse oximeter or no data transfer from pulse oximeter to tablet at time of arterial blood gas test).
(2) Technical error in performance or analyse of arterial blood gas test.
In case of doubt, a consensus was reached in cooperation with KS.
Clinical and paraclinical parameters
The following clinical and paraclinical parameters were collected from the electronical patient record (MidtEPJ, Systematics, Aarhus, Denmark): SSc-disease characteristics, (ii) medication, (iii) modified Rodnan Skin score (mRSS), (iv) routine blood samples, (v) electrocardiogram (ECG), (vi) the latest pulmonary function test (PFT, median time since latest PFT was 10 months [interquartile interval(IQI): 2–18]), (vii) the latest high-resolution computed tomography (HRCT, median time since latest HRCT was 72 months [IQI: 20–113]), (viii) the latest transthoracic echocardiography, (ix) PAH detected by right-heart catheterisation, and (x) comorbidities. SSc-ILD was defined according to the HRCT criteria for ILD patterns [19].
All patients had Nailfold Videocapillaroscopy (NVC) images recorded of the 2nd to 5th finger. The capillary density was assessed with the 90-degree method from minimum 3 images per patient. The general capillary density was defined as the mean capillary density of the available pictures from the same hand.
Patient-related outcome measures
Patients answered two self-reporting questionaries: Raynaud’s attacks the last month, including the Raynaud’s Condition Score (RCS) [20] and burden of ischaemic ulcers, and the Scleroderma Health Assessment Questionnaire (SHAQ) [21].
Statistical analysis
Categorial data are reported as counts and percentages, and continuous data as mean values and standard deviation (± SD) when normally distributed or otherwise as median values and interquartile interval (IQI). Data distribution was investigated Q–Q plots and histograms.
The agreement of the SpO2 of the three anatomical sites was examined using Bland–Altman plots to display the difference between SpO2 and SaO2 (bias) at pre-exercise and at post-exercise [22], and the re-test reliability was examined using Bland–Altman plots to display the agreements between the minimum SpO2 during the 6MWT, the 6MWD and Borg dyspnea score at visit 1 and visit 2. Furthermore, the overall accuracy of the peripheral oxygen measurement was calculated by the accuracy root mean square (Arms) (√ [(bias)2 + (precision)2) [23]. In accordance with the Food and Drug Administration recommendation, we used a cut-off of Arms < 3% as the acceptable accuracy of the SpO2 measurements [24].
The intraclass correlation coefficient (ICC, 95% confidence interval [95% CI]) for repeated measurement of minimum SpO2 was calculated based on an absolute agreement, two-way mixed effect model [25]. The ICC values were interpreted using the following definitions: ICC < 0.5: poor reliability, ICC: 0.5–0.75: moderate reliability, ICC 0.75–0.9: good reliability, and ICC > 0.90: excellent reliability. Furthermore, we calculated the frequency of measurement error of SpO2 at post-exercise for the finger, forehead, and earlobe sensors. Measurement errors was defined as values being ± 4% different from SaO2 values. In explorative analysis, we examined the impact of demographic parameters, comorbidities, and SSc specific parameters on the risk of measurement errors of the SpO2. Statistical significance was tested using Student’s t test, the nonparametric Mann–Whitney U test and Fisher’s exact test. All analyses were carried out in Stata17, where p < 0.05 was considered statistically significant.
Ethical permissions
The research project was approved by the Central Denmark Region Committees on Health Research Ethics (1-10-72-203-20) at the 30 October 2020 and listed in the Central Denmark Region register of internal research projects (1-16-02-270-20) at the 15 June 2020. ClinicalTrials.gov identifier: NCT04650659.
RESULTS
Patient characteristics and baseline characteristics
One hundred ninety-nine patients were screened for the study. Sixteen patients were excluded from the study, and 101 patients chose not to participate. In total, 82 patients participated in our study (Supplementary Fig. 3).
The patients had a median age of 58 years (IQI: 52–66), and 76% of patients were female (Table 1). Thirty-seven patients (45%) had either SSc-ILD or PAH. None of the included patients needed supplemental oxygen or walking aid during 6MWT.
Table 1.
Baseline characteristics of patients (n = 82)
| Variable | ||
|---|---|---|
| Demographics | ||
| Age, years, median (IQI) | 58 | (52–66) |
| Females, n (%) | 62 | (76%) |
| Smoking, n (%) | ||
| Current smokers | 30 | (37%) |
| Ex-smokers | 44 | (54%) |
| Never smokers | 8 | (10%) |
| Systemic sclerosis disease characteristics | ||
| Disease duration*, years, median (IQI) | 8 | (4–12) |
| Skin involvement, n (%) | ||
| Limited cutaneous | 42 | (51%) |
| Diffuse cutaneous | 38 | (46%) |
| Sine scleroderma | 2 | (2%) |
| mRSS**, median (IQI) | 4 | (2–6) |
| mRSS** on fingers only, median (IQI) | 1 | (1–2) |
| Autoantibodies, n (%) | ||
| ACA | 34 | (42%) |
| Anti-SCL-70 | 15 | (18%) |
| Anti-RNA polymerase III | 3 | (4%) |
| Anti U1 RNP | 8 | (10%) |
| Anti Th/To | 2 | (2%) |
| Organ manifestations, n (%) | ||
| Gastrointestinal | 69 | (84%) |
| Arthritis | 27 | (33%) |
| Myositis | 13 | (16%) |
| ILD | 35 | (43%) |
| Pulmonary hypertension | 2 | (2%) |
| SHAQ: Disease severity, median (IQI) | 1 | (0–2) |
| Results of pulmonary tests | ||
| Latest lung function parameters, median (IQI) | ||
| FEV1, % predicted | 96 | (85–107) |
| FVC, % predicted | 104 | (93–115) |
| DLCO, % predicted | 69 | (52–84) |
| Latest high-resolution CT-scan, n (%) | ||
| Sign of interstitial lunge disease | 35 | (42.7%) |
| Extent of interstitial features [36] (n = 35) | ||
| 0–15 % | 16 | (46%) |
| 15–25 % | 6 | (17%) |
| > 25 % | 12 | (34%) |
| Unknown | 1 | (3%) |
| Echocardiography, n (%) | ||
| Reduced left ventricular ejection fraction | 2 | (2%) |
| Diastolic dysfunction | 8 | (10%) |
| Respiratory symptoms, n (%) | ||
| NYHA I | 41 | (6%) |
| NYHA II | 25 | (33%) |
| NYHA III / IV | 15 | (18%) |
| Unknown | 1 | (1%) |
| Microvascular disease of the fingers | ||
| RCS, median (IQI) | 3 | (0–6) |
| History of ischemic digital ulcers, n (%) | 28 | (31%) |
| Current use of vasodilator, n (%) | 64 | (78%) |
| Comorbidity, n (%) | ||
| Cardiovascular disease | 28 | (34%) |
| COPD and/or asthma | 9 | (11%) |
| Arthrosis in the knees and/or hips | 15 | (18%) |
| Diabetes mellitus | 3 | (4%) |
*Disease duration among 60/82 who could recall years of first SSc-related symptom (not Raynaud Syndrome)
**mRSS evaluated at the latest clinical visit
IQI Interquartile interval, mRSS modified Rodnan Skin Score, ACA Anti-Centromere Antibody, Anti-SCL-70 Anti-Topoisomerase I, SHAQ Scleroderma Health Assessment Questionnaire, FEV1 Forced Expiratory Volume in 1 s, FVC Forced Vital Capacity, DLCO Diffusing Capacity of Carbon Monoxide, ILD Interstitial lung disease, NYHA New York Heart Association, RCS Raynaud’s Condition Score, COPD Chronic obstructive pulmonary disease and SSc Systemic sclerosis
The median 6MWD was 564 m (IQI: 502–622) during the first 6MWT, while the SaO2 was 97% (IQI: 97–98) and 97% (IQI: 96–98) at pre- and post-exercise (Supplementary Table 2), respectively. During the 6MWT, 46 of the patients (56%) had visual signs of Raynaud’s attack, and desaturation below 88% were registered in 28%, 17% and 8% of the patients the by probes on the finger, forehead, and earlobe respectively (Supplementary Table 2).
Validity of peripheral oxygen measurement
The agreements between measurement of SpO2 and SaO2 are shown in Fig. 1 and Table 2. The Finger probe measurements underestimated the arterial saturation (SpO2(pre-exercise) = − 0.7% and SpO2(post-exercise) = − 3.3%). At post-exercise, the ARMS was 5.8% and we observed wide limits of agreement between measurement of SpO2 and SaO2 (95% limit of agreement: − 6–12%).
Fig. 1.
Bland–Altman plots showing the validity of measurement of peripheral oxygen saturation at the finger, earlobe, and forehead. Black circles: values with ≤ ± 4% difference between SpO2 and SaO2 values. Hollow circle: values with > ± 4% difference between SpO2 and SaO2 values. Solid line: Mean difference between SpO2 and SaO2 (bias). Dashed lines: lower and upper limits of agreement. Mean difference < 0%: SpO2 underestimates SaO2. Mean difference > 0%: SpO2 overestimates SaO2. SpO2 Peripheral oxygen saturation, SaO2 Arterial oxygen saturation
Table 2.
Bias, precision and accuracy of peripheral oxygen measurements during 6MWT
| Probe location | Number of valid measurements | Bias (SpO2–SaO2) | Standard deviation | Accuracy (ARMS) |
|---|---|---|---|---|
| Finger | ||||
| Pre-test | 73 | − 0.7% | 1.9% | 1.9% |
| Post-test | 78 | − 3.3% | 4.8% | 5.8% |
| Earlobe | ||||
| Pre-test | 75 | 1.5% | 0.8% | 1.7% |
| Post-test | 77 | 1.3% | 2.0% | 2.4% |
| Forehead | ||||
| Pre-test | 64 | 0.0% | 1.3% | 1.3% |
| Post-test | 76 | 0.2% | 1.6% | 1.6% |
6MWT 6-Minute Walk Test, ARMS Accuracy root mean square
The earlobe and forehead both overestimated the arterial oxygen saturation (earlobe SpO2(post-exercise) = 1.3 and forehead SpO2(post-exercise) = 0.2%). At post-exercise, the ARMS was < 3% and the limit of agreement between measurement of SpO2 and SaO2 was narrower for the earlobe and forehead than that was seen for the finger probe (earlobe: 95% limits of agreement: -2.5% to 5.2% and forehead: 95% limits of agreement: -2.9% to 3.2%).
Measurement error of peripheral oxygen measurement
Measurement errors (> ± 4% difference between SpO2 and SaO2 values) of peripheral oxygen saturation are highlighted with a hollow circle in Fig. 1. At post-exercise, measurement errors were registered in 23%, 3%, and 1% of the patients by the finger, earlobe, and forehead probe, respectively.
In patients with measurement error by the finger probe, 16/20 of patients (89%) had Raynaud’s attack during the 6MWT (p = 0.001), and 17/20 of patient (95%) received vasodilator treatment for SSc-related microvasculopathy (p < 0.05) (Table 3).
Table 3.
Clinical and test data of patients with and without measurement error using finger probe at post-exercise (n = 78) (Measurement error ± 4% between SpO2 and SaO2)
| Patients without measurement error using finger probe (n = 58) | Patient with measurement error using finger probe (n = 20) | p value | |||
|---|---|---|---|---|---|
| Variable | |||||
| Demographic | |||||
| Age, median (IQI) | 58 | (50–65) | 58.5 | (52.5–68) | 0.60 |
| Sex (female gender), n (%) | 43 | (74.1) | 15 | (75.0) | 1.00 |
| Current smoking, n (%) | 7 | (12.1) | 1 | (5.0) | 0.67 |
| Comorbidity | |||||
| Cardiovascular disease*, n (%) | 4 | (6.9) | 3 | (15.0) | 0.37 |
| Diabetes mellitus, n (%) | 1 | (1.8) | 2 | (10.0) | 0.16 |
| COPD and/or asthma, n (%) | 6 | (10.3) | 2 | (10.0) | 1.00 |
| Skin involvement | |||||
| Disease duration*, years, median (IQI) | 8 | (4–14) | 8 | (4–14) | 0.75 |
| Modified Rodnan skin score on digits, mean (SD) | 0.9 | (0.6) | 1.2 | (0.7) | 0.20 |
| Skin involvement, n (%) | |||||
| Limited | 30 | (52) | 9 | (45) | 0.71 |
| Diffuse | 27 | (47) | 11 | (55) | |
| Sine | 1 | (1.7) | 0 | (0.0) | |
| Microvascular involvement | |||||
| Raynaud’s Condition Score***, median (IQI) | 3 | (1–5) | 4.5 | (2.5- 6) | 0.19 |
| History of digital ulcers, n (%)a | 16 | (30.2%) | 9 | (45%) | 0.28 |
| Current use of vasodilators, n (%) | 41 | (71%) | 19 | (95%) | < 0.05* |
| General capillary density****, mean (SD) | 6.9 | (1.6) | 6.4 | (0.9) | 0.31 |
| Modified Rodnan skin score on digits, mean (SD) | 0.9 | (0.6) | 1.2 | (0.7) | 0.20 |
| Raynaud’s phenomenon observed during 6MWT, n (%) | 25 | (43.1%) | 18 | (90.0%) | < 0.001* |
| Pulmonary involvement | |||||
| Signs of interstitial lung disease on HRCT, n (%) | 23 | (39.7) | 12 | (60.0) | 0.13 |
| Pulmonary arterial hypertension | 2 | (3.5) | 0 | (0.0) | 0.78 |
*Cardiovascular disease: ischaemic heart disease, heart failure, atrial fibrillation, stroke and peripheral vascular disease,
**Disease duration among 67/78 who could recall years of first SSc-related symptom (not Raynaud Syndrome), ***73 number of valid measurements,**** 41 number of valid measurements
6MWT 6-Minute Walk Test, IQI interquartile interval, SD standard deviation, SaO2 Arteriel oxygen saturation, SpO2 peripheral oxygen saturation
Re-test reliability of the minimum peripheral oxygen saturation
The mean differences of the minimum SpO2 (visit2-visit1) during the 6MWT was 1% (SD: ± 5), 1% (SD: ± 4) and − 1% (SD: ± 3) for the finger, forehead, and earlobe, respectively (Fig. 2). The ICC showed good agreement using the ear and forehead probe (ICCear = 0.89 [0.80; 0.94]; ICCforehead = 0.77 [0.60; 0.87]), while a modest reliability was found using the finger probe (ICCfinger = 0.65 [0.43; 0.80]). The Mean difference of the 6MWD (visit2-visit1) was 9m (SD: ± 2).
Fig. 2.
Bland–Altman plots for the re-test reliability of the minimum peripheral oxygen saturation. Solid line: Mean difference between minimum SpO2 (visit 2-visit 1). Dashed lines: lower and upper limits of agreement. Mean difference > 0: MinSpO2 at visit 2 > minSpO2 at visit 1. Mean difference < 0: MinSpO2 at visit 2 > minSpO2 at visit 1
The mean difference of the post-exercise Borg dyspnoea score (visit2-visit1) was 0 (SD: ± 2) (Supplementary Fig. 3).
Discussion
This study showed that measurement of SpO2 using the finger sensor was inaccurate and underestimated the SaO2. Furthermore, we demonstrated that SpO2 measured at the earlobe and forehead had a high validity and re-test reliability. Indeed, using the finger measurement during the 6MWT resulted in measurement error of saturation in 23% of patients with SSc, with SpO2 values being ± 4% different from the SaO2.
The poor accuracy of finger measurements of SpO2 may be explained by Raynaud’s phenomenon and the peripheral microvasculopathy in patients with SSc, which lead to inaccurate measurements of SaO2 due to poor perfusion and hypothermia of the fingers. Indeed, measurement error by the finger probe was primary seen in patients with Raynaud’s attack during the 6MWT and was associated with the use of vasodilator treatment. Several studies have shown impaired perfusion and reduced oxygen delivery in the digital arteries in patients with SSc compared to healthy controls [26–29]. Furthermore, the accuracy of using finger probes in SSc is challenged by variability in measurements of SpO2 among fingers in patients with SSc. On the other hand, a recent study reported that blood perfusion of the skin in the face was not different at rest in patients with SSc compared to healthy individuals [14]. Thus, our findings support that oximetry areas that are not affected by Raynaud’s phenomenon, should be used during the 6MWT in patients with SSc.
Swigris et al. examined the accuracy of finger SpO2 measurement and the prognostic value of desaturation in 83 SSc patients during a cardiopulmonary exercise test [11]. While this study found that the finger SpO2 overestimated the SaO2, the limits of agreement for the mean difference of finger SpO2 and SaO2 were wide at maximum exercise as in our study. Furthermore, the study also found that desaturation defined as SpO2 below 89% or SpO2 fall > 4 points during maximal exercise was associated with a higher mortality. Therefore, it is a crucial finding in our study that the measurement error of the finger probe in a significant proportion of patients had SpO2 values being ± 4% different from SaO2.
Only one previous study has examined the re-test reliability of peripheral oxygen saturation at different anatomical sites during the 6MWT in patients with SSc. Compared to our study, there was only moderate agreement of forehead and finger SpO2 measurements during two 6MWT while the agreement for the earlobe SpO2 was poor [7]. Still, this study was small (N = 25), and it was only possible to obtain reliable measurements using the earlobe probe in a minority of patients (n = 7). In our study, the post-exercise Borg dyspnoea score and the 6MWD were similar at both visits which is in line with other studies that also found good reproducibility of the 6MWD in patients with SSc [7, 30, 31].
The main strength of this study was the large number of prospectively recruited SSc patients and the fact that we were able to compare measurements of continuous SpO2 at three different anatomical locations with the arterial saturation as the gold standard. Still, due to the study setup, we were only able to measure arterial oxygen saturation pre- and post-exercise (averagely 20 s post-exercise) and, therefore, the lowest arterial oxygenation may have occurred during the 6MWT. In addition, we were not able to measure oxygen saturation in all patients due to either technical error in collection of data from pulse oximeters or failure in performing or analyzing the blood gas analysis. Last, due to the dynamic performance of the 6MWT, we may not have visually registered all cases of Raynauds’ attacks.
In our study, 43% of the patients had signs of ILD which is similar to the proportion of SSc patients with pulmonary fibrosis in the EUSTAR database [32]. Furthermore, the post-exercise Borg dyspnoea scores were similar to other studies of the 6MWT in patients with SSc [7, 30, 31, 33, 34]. Still, our results are based on only a single center using a specific pulse oximeter. Hence, the disease characteristics of the SSc may be different in other setting and our results may not be representative for other pulse oximetry sensors.
Conclusion
The present study showed a high accuracy for measuring the SpO2 using the earlobe or forehead during the 6MWT in patients with SSc. Furthermore, we demonstrated that finger measurement of SpO2 has poor validity and that measurement error of SpO2 was associated with markers of peripheral vasculopathy in SSc. The preferred method for monitoring SpO2 in clinical SSc-trials and in the monitoring of SSc patients should be at the forehead or the earlobe.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
We thank all patients for participating in the study. The authors also wish to thank physiotherapists Trine Seneca and Louise Korsgaard Christensen for their guidance in performing the 6MWT.
Author contributions
All authors made substantial contributions to the conception or design of the study or the acquisition, analysis, or interpretation of data. ALE and EN drafted the first manuscript, and all authors were involved in revising it critically for important intellectual content, and approved the version to be published. Finally, all authors agreed to be accountable for appropriate portions for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Funding
Open access funding provided by Aarhus University Hospital. This work was supported by the Danish Rheumatism Association [grant numbers: R185-A6640 and R192-A6758]. The funding source had no involvement in study design; collection, analysis, and interpretation of data; writing of the report; or in the decision to submit the article for publication.
Declarations
Conflicts of interest
E Næser reports lecture fees from Boehringer Ingelheim. HL Hovgaard reports unrestricted research grant from Aarhus University and the Novo Nordisk Foundation; travel support from Aarhus University. K Søndergaard reports unrestricted research grants from Boehringer Ingelheim and the Danish Rheumatism Association. K Søndergaard also reports consultant and lecturing fees from Boehringer Ingelheim; travel fees from UCB. E Bendstrup reports lecture fees from Boehringer Ingelheim, Daiichi-Sankyo, and Astra Zeneca. E Bendstrup also reports; travel and congress, and consulting fees from Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Ethics approval
The research project was approved by the Central Denmark Region Committees on Health Research Ethics (1-10-72-203-20) and listed in the Central Denmark Region register of internal research projects (1-16-02-270-20). ClinicalTrials.gov identifier: NCT04650659.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Footnotes
A congress publication is available from the EULAR 2023 European Congress of Rheumatology: A. Lynggaard Riis, E. Naeser, K. T. Aaen, H. Hovgaard, P. Juhl-Olsen, E. Bendstrup, K. Soendergaard. AB0821 VALIDITY AND RELIABILITY OF MEASUREMENT OF PERIPHERAL OXYGEN SATURATION DURING THE 6-MINUTE WALK TEST IN PATIENTS WITH SYSTEMIC SCLEROSIS Annals of the Rheumatic Diseases Jun 2023, 82 (Suppl 1): 1623.2-1624; DOI; http://dx.doi.org/10.1136/annrheumdis-2023-eular.3244. No part of this report is copied or published elsewere in whole or in part.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Amanda Lynggaard Elkjær and Esben Uggerby Næser contributed equally to this study.
References
- 1.Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–1815. doi: 10.1136/ard.2009.114264. [DOI] [PubMed] [Google Scholar]
- 2.Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015 doi: 10.1038/nrdp.2015.2. [DOI] [PubMed] [Google Scholar]
- 3.Cuomo G, Santoriello C, Polverino F, et al. Impaired exercise performance in systemic sclerosis and its clinical correlations. Scand J Rheumatol. 2010;39:330–335. doi: 10.3109/03009740903555358. [DOI] [PubMed] [Google Scholar]
- 4.ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS Statement: The Six-Minute Walk Test. Am J Respir Crit Care Med. 2002;166:111–117. doi: 10.1164/rccm.166/1/111. [DOI] [PubMed] [Google Scholar]
- 5.Rizzi M, Radovanovic D, Santus P, et al. Usefulness of six-minute walk test in systemic sclerosis. Clin Exp Rheumatol. 2018;36(Suppl 113):S161–S167. [PubMed] [Google Scholar]
- 6.Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest. 2007;131:217–222. doi: 10.1378/chest.06-0630. [DOI] [PubMed] [Google Scholar]
- 7.Wilsher M, Good N, Hopkins R, et al. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology. 2012;17:647–652. doi: 10.1111/j.1440-1843.2012.02133.x. [DOI] [PubMed] [Google Scholar]
- 8.Schoindre Y, Meune C, Dinh-Xuan AT, et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol. 2009;36:1481–1485. doi: 10.3899/jrheum.081221. [DOI] [PubMed] [Google Scholar]
- 9.Ariani A, Aiello M, Silva M, et al. Quantitative CT indexes are significantly associated with exercise oxygen desaturation in interstitial lung disease related to systemic sclerosis. Clin Respir J. 2017;11:983–983. doi: 10.1111/crj.12451. [DOI] [PubMed] [Google Scholar]
- 10.Wu W, Jordan S, Becker MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model. Ann Rheum Dis. 2018;77:1326–1332. doi: 10.1136/annrheumdis-2018-213201. [DOI] [PubMed] [Google Scholar]
- 11.Swigris JJ, Zhou X, Wamboldt FS, et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax. 2009;64:626–630. doi: 10.1136/thx.2008.111393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pathania YS. Alternatives for erroneous finger probe pulse oximetry in systemic sclerosis patients during COVID-19 pandemic. Rheumatol Int. 2021;41:2243–2244. doi: 10.1007/s00296-021-05032-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Garg R, Verma S. Pulse oximetry in scleroderma patients. Acta Anaesthesiol Scand. 2008;52:1303. doi: 10.1111/j.1399-6576.2008.01667.x. [DOI] [PubMed] [Google Scholar]
- 14.Akdogan A, Kilic L, Dogan I, et al. Effect of capillaroscopic patterns on the pulse oximetry measurements in systemic sclerosis patients. Microvasc Res. 2015;98:183–186. doi: 10.1016/j.mvr.2014.02.002. [DOI] [PubMed] [Google Scholar]
- 15.van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2013;72:1747–1755. doi: 10.1136/annrheumdis-2013-204424. [DOI] [PubMed] [Google Scholar]
- 16.Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12:363–373. doi: 10.1016/j.autrev.2012.06.004. [DOI] [PubMed] [Google Scholar]
- 17.Holland AE, Spruit MA, Troosters T, et al. An official European respiratory society/American thoracic society technical standard: Field walking tests in chronic respiratory disease. Eur Respir J. 2014;44:1428–1446. doi: 10.1183/09031936.00150314. [DOI] [PubMed] [Google Scholar]
- 18.Vyaire Medical (2019) VyntusTM WALK. Truly mobile - six minute walk test. https://www.vyaire.com/sites/us/files/2023-04/VYR-GLB-1900001_Brochure_Vyntus_Walk_03_EN_view_0.pdf. Accessed 20 Dec 2023
- 19.Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002;46:2410–2420. doi: 10.1002/art.10486. [DOI] [PubMed] [Google Scholar]
- 21.Pope J. Measures of systemic sclerosis (scleroderma) Arthritis Care Res (Hoboken) 2011;63:98–111. doi: 10.1002/acr.20598. [DOI] [PubMed] [Google Scholar]
- 22.Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Int J Nurs Stud. 2010;47:931–936. doi: 10.1016/j.ijnurstu.2009.10.001. [DOI] [PubMed] [Google Scholar]
- 23.Poorzargar K, Pham C, Ariaratnam J, et al. Accuracy of pulse oximeters in measuring oxygen saturation in patients with poor peripheral perfusion: a systematic review. J Clin Monit Comput. 2022;36:961–973. doi: 10.1007/s10877-021-00797-8. [DOI] [PubMed] [Google Scholar]
- 24.FDA Administration Pulse oximeter accuracy and limitations: FDA safety communication. In: 2021. https://www.fda.gov/medical-devices/safety-communications/pulse-oximeter-accuracy-and-limitations-fda-safety-communication. Accessed 20 Dec 2023
- 25.Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15:155–163. doi: 10.1016/j.jcm.2016.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Zhang W, Xu JR, Lu Q, et al. High-resolution magnetic resonance angiography of digital arteries in SSc patients on 3 Tesla: Preliminary study. Rheumatology. 2011;50:1712–1719. doi: 10.1093/rheumatology/keq453. [DOI] [PubMed] [Google Scholar]
- 27.Mugii N, Hasegawa M, Hamaguchi Y, et al. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology. 2009;48:696–703. doi: 10.1093/rheumatology/kep066. [DOI] [PubMed] [Google Scholar]
- 28.Ruaro B, Sulli A, Pizzorni C, et al. Correlations between skin blood perfusion values and nailfold capillaroscopy scores in systemic sclerosis patients. Microvasc Res. 2016;105:119–124. doi: 10.1016/j.mvr.2016.02.007. [DOI] [PubMed] [Google Scholar]
- 29.Akdogan A, Sari A, Sener YZ, et al. Association between oxygen delivery and digital ulcers in systemic sclerosis. Microvasc Res. 2023;145:104449. doi: 10.1016/j.mvr.2022.104449. [DOI] [PubMed] [Google Scholar]
- 30.Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: Reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007;66:169–173. doi: 10.1136/ard.2006.054866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Pugnet G, Marjanovic Z, Deligny C, et al. Reproducibility and utility of the 6-minute walk test in systemic sclerosis. J Rheumatol. 2018;45:1273–1280. doi: 10.3899/jrheum.170994. [DOI] [PubMed] [Google Scholar]
- 32.Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66:754–763. doi: 10.1136/ard.2006.062901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sanges S, Giovannelli J, Sobanski V, et al. Factors associated with the 6-minute walk distance in patients with systemic sclerosis. Arthritis Res Ther. 2017;19:1–11. doi: 10.1186/s13075-017-1489-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Deuschle K, Weinert K, Becker M, et al. Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S53–S59. [PubMed] [Google Scholar]
- 35.S. L Goh N, Sujal R. D, Srihari V, , et al. Interstitial lung disease in systemic sclerosis. Am J Respir Crit Care Med. 2008;177:1248–1254. doi: 10.1164/rccm.200706-877oc. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.